LIPRAB 20
Extinguishes Hyperacidity... Restores Comfort
It is a drug that is used for the treatment of conditions caused by acid. It is in a class of drugs called proton pump inhibitors or PPIs which block the production of acid by the stomach. It blocks the pump in the wall of the stomach that secretes acid into the stomach. By blocking the pump, the secretion of acid into the
stomach is decreased, and this allows ulcers in the stomach and esophagus to heal.
INDICATIONS:
• Gastric ulcer (GU)
• Peptic ulcer disease (PUD)
• Maintenance of healing of erosive or ulcerative GERD
• Healing of erosive and ulcerative GERD
• Healing of duodenal ulcers.
• Treatment of symptomatic GERD
• Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
• Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence
___________________________________________________________________________________
LIPRAB-DSR
It is the combination of rabeprazole and domperidone. It prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastro esophageal reflux disease or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome and may also be used with antibiotics to get rid of bacteria that are associated with some ulcers. Domperidone is a dopamine antagonist with anti-emetic properties and does not readily cross the blood-brain barrier.
INDICATIONS:
GERD, heart burn, hyperacidity, reflux oesophagitis, regurgitation and flatulence, gastric and peptic ulcer.
__________________________________________________________________________________
SUCRALIP
Gastro-protection from occurrence and recurrence of Peptic Ulcers
Sucralip is a unique oral drug that is used for treating ulcers of the upper gastrointestinal tract. Its actions are entirely on the lining of the stomach and duodenum. It prevents acid, pepsin & bile from coming in contact with ulcer base and inhibits Hcl acid penetration and stops mucosal perforation.
INDICATION:
Duodenal ulcers
Reflux oesophagitis
Bile reflux
Chronic gastritis.
___________________________________________________________________________________
SUCRALIP-O
Sucralip is a unique oral drug that is used for treating ulcers of the upper gastrointestinal tract. Its actions are entirely on the lining of the stomach and duodenum. It prevents acid, pepsin & bile from coming in contact with ulcer base and inhibits Hcl acid penetration and stops mucosal perforation. Oxethazaine is an ideal G.I. anaesthetic agent and controls pain associated with ulcer.
INDICATIONS:
Duodenal ulcers
Reflux oesophagitis
Bile reflux
Chronic gastritis
Gastric ulcers
NSAID/Antibiotic induced neuropathy
__________________________________________________________________________________
LIPRAB SUSP.
It is used for treating acid indigestion, heartburn, gas, and sour stomach. Magaldrate/simethicone suspension is an antacid and antiflatulent combination. The antacid works by neutralizing stomach acid and increasing the pH of the stomach. The antiflatulent works by breaking up gas bubbles, which makes gas easier to eliminate.
Indications:
This medicine is used to relieve excess gas in the stomach.
This medicine is used to treat heartburn and indigestion.
Antacids reduce stomach acid.
Simethicone relieves the pressure caused by gas.
__________________________________________________________________________________
PANTEST-IV INJ.
Top Class Proton Pump Inhibitor
It belongs to the category of proton pump inhibitors (PPIs) reduce the amount of acid made by your stomach. They are commonly used to treat acid reflux and ulcers of the stomach and duodenum.
___________________________________________________________________________________
PANTEST-40
It blocks the enzyme in the wall of the stomach that produces acid. By blocking the enzyme, the production of acid is decreased, and this allows the stomach and esophagus to heal.
INDICATIONS:
Pantoprazole is primarily indicated in conditions like Benign gastric ulcer, Duodenal ulcer, gastric ulcer, Duodenal ulcer associated with h. Pylori, Esophagitis, Gastro-oesophageal reflux disease, Oesophagitis, Peptic ulcer, Prophylaxis of NSAID-associated gastric or duodenal ulcer and Zollinger-ellison syndrome,
___________________________________________________________________________________
PANTEST-D
This combination medication contains proton pump inhibitor and an antidopaminergic agent. Pantoprazole acts by selectively inhibiting the H+/K+-ATPase enzyme in the secretory canaliculus of the stimulated parietal cell. Domperidone stimulates GI activity by acting as a competitive antagonist at dopamine D2-receptors.
INDICATIONS:
Dyspepsia, GERD.
Mr.K Ragunathan, (48)
Chairman
The pharmaceutical industry needs a high level of consistency in terms of quality of drugs and medicines they manufacture and continue to strive for honouring commitments to clients. Globally there have been concerted efforts to monitor quality and regulate pharma operations for quality health care being extended to the target population.
Towards this end, we at Lipak India are constantly evolving to newer heights by placing our focus on Products, Processes and People as central themes to guide our business philosophy. With Innovation being a value driver, our strategic planning started in early 2011 with an ideation session analysing Lipak India's current strengths, weaknesses, opportunities and threats. We will be continuing our dialogue on strategic planning throughout the next several months, looking at financial health, research and development focus, management structure, operational efficiency, risk management, stakeholder communication, shareholder wealth creation and corporate social responsibility.
By the end of this process, we will be credited with a clear road map that will help us navigate smoothly through the challenges ahead.
Over the last decade many pharma organisations across India have started adopting various excellence initiatives. These initiatives are supposed to aid organisations in creating value and help face the challenging business needs. Let me hasten to add that Lipak India has seized this opportunity by adopting certain companywide initiatives such as management restructuring, venturing into newer business portfolios, enterprise resource planning, setting up HR governing council and adoption of operational excellence cell apart from culling out task force teams in quality and R&D with a view to provide the best pharma solutions to our esteemed clients
Lipak India stands today as one of the few distinguished vertically integrated pharmaceutical companies with a robust product portfolio produced out of our own approved manufacturing facilities, both in the areas of API and Formulations, with enviable longstanding business partnerships.
Over the years, we have grown from strength to strength and our global team of more than 9,500 scientists, technicians, sales, marketing, financial, manufacturing, quality, administrative and other business professional’s work together to achieve our global mission - "Committed to healthier life”.
We are sure that with the continued support and patronage of all our stakeholders, Lipak India will continue to enjoy the saga of business excellence in the healthcare sector in the coming periods, cutting across geographical boundaries.
We are Lipak India Ltd. “A global pharmaceutical company with great commitment to a healthier life".
